## **Clinical Trials**

**Clinical Trial:** 

Perioperative Ischemic Evaluation-3 (POISE-3) - Clinical Trial:

The Project of POISE-3 is sponsored by the Population Health Research Institute, Hamilton Health Sciences Corporation, Canada. Dr. Muhammad Amir from Shifa International Hospitals Ltd, Islamabad is heading this project as Principal Investigator (PI).

Clinical Trial:
Can Sino COVID Vaccine:

Pakistan is among 07 countries that will carry out the Phase III trial in compliance with National and International Ethical & Regulatory Guidelines. Dr. Ejaz A. Khan, Principal Investigator, on behalf of Shifa International Hospitals and Shifa Foundation (SCOPE) signed the agreement with CanSino Pharmaceuticals and National Institute Health (NIH).

Clinical Trial: LIVZON:

The Third phase of this multicenter, randomized, and double blind placebo controlled trial for COVID-19 was launched. Dr. Mian Amjad Sohail represented Shifa International Hospitals, Ltd and Shifa Foundation (SCOPE) as Principal investigator.

**Clinical Trial:** 

<u>Colchicine for The Prevention of perioperative Atrial</u>
Fibrillation in Patients Undergoing Thoracic Surgery (COP-AF):

The Project of COP-AF is sponsored by the Population Health Research Institute, Hamilton Health Sciences Corporation, Canada. Dr. Muhammad Amir from Shifa International Hospitals Ltd, Islamabad is heading this project as Principal Investigator (PI).